SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$4.83 USD
-0.01 (-0.21%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $4.88 +0.05 (1.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SOPH 4.83 -0.01(-0.21%)
Will SOPH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SOPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SOPH
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
SOPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Other News for SOPH
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDMâ„¢ Platform
SOPHiA GENETICS: Pioneering Equitable Healthcare
Tracking Al Gore's Generation Investment Management Portfolio - Q1 2024 Update
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
Sophia Genetics launches SOPHia UNITY to accelerate cancer research